Russian registry of resistant arterial hypertension (REGATTA): study design


Cite item

Full Text

Abstract

Design of Russian Registry of Resistant Arterial Hypertension Trial (REGATTA) is described. In the REGATTA trial clinical and epidemiological features of resistant and uncontrolled arterial hypertension will be characterized, as well as efficacy of fixed combination of amlodipine and valsartan

References

  1. Российское Медицинское общество по артериальной гипертонии - Всероссийское научное общество кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр.). М., 2008.
  2. Cushman WC, Ford CE, Cutler JA, et al. for the ALLHAT Collaboratyive Research Group. Success and predictors of blood pressure control in diverse North American Settings: the Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002;4:393-404.
  3. Garg JP, Elliott WJ, Folker A, et al. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005;18(5 Pt. 1):619-26.
  4. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens 2001;14(12):1263-69.
  5. Чазова И.Е., Фомин В.В. Резистентная артериальная гипертензия // Терапевтический архив. 2008. № 6. С. 72-79.
  6. Sloand JA, Balakroshnan SL, Fong MW, et al. Evaluation and treatment of resistant hypertension. Cardiology J 2007;14(4):329-39.
  7. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation and teratment: A scientific statement form the American Heart Association professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510-e526.
  8. Ouzan J, Perault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002;15(4 Pt. 1):333-39.
  9. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49(4):839-45.
  10. Stowasser M, Gordon RD, Gunasekera TG, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens 2003;21(11):2149-57.
  11. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the insidence of hypertension in nonhypertensive persons. N Engl J Med 2004;351:33-42.
  12. Rodilla E, Costa JA, Perez-Lahiguera F, et al. Spironolactone and doxazosin treatment in patients with resistant hypertension. Rev Esp Cardiol 2009;62(2):158-66.
  13. Ceral J, Solar M. Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension. Blood Press 2009;18(1):74-77.
  14. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-81.
  15. Alleman Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients uncontrolled with monotherapy: the Exforge in Failure after Single Therapy (Ex-FAST) Study. J Clin Hypertens (Greenwich) 2008;10(3):185-94.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies